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Abstract
            Electrical storm occurring in a patient with the Brugada syndrome is an exceptional but
malignant and potentially lethal event. Efficient therapeutic solutions should be known and
urgently applied because of the inability of usual antiarrhythmic means in preventing multiple 
recurrences of ventricular arrhythmias. Isoproterenol should be immediately infused while oral
quinidine should be further administrated when isoproterenol is not effective. In case of failure of
these therapeutic options, ablation of the triggering ventricular ectopies should be attempted
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The Brugada syndrome is an inherited cardiac electrical disorder occurring in the absence of
obvious structural heart disease, initially defined by the association of right bundle branch block,
ST elevation in right precordial leads and sudden cardiac death related to polymorphic
ventricular tachycardias 1.
In Brugada syndrome, the prevalence of malignant ventricular arrhythmias varies from 5 % at
two years follow-up in asymptomatic patients to 45 % in patients with previous cardiac arrest 2.
While in most patients, a single arrhythmic event occurs, some patients will suffer electrical
storms. Although there is no commonly accepted definition for this event, electrical storm is
generally perceived as the rapid or incessant succession of recurrent poorly tolerated ventricular
arrhythmias, generally requiring repeated cardioversions, occurring during a short period of time
3,4 (Figure 1). Electrical storm is fortunately a very scarce phenomenon, but which can occur
twice or more in the same patient 5,6, or can be the first manifestation of the disease 7,8.
            True prevalence of electrical storm in Brugada syndrome has not been evaluated, such
events having only been seldom reported in isolated case reports. To our knowledge, to date, only
twelve such cases have been published 5-16.
Although exceptional, electrical storm in Brugada syndrome is a major event with dramatic
consequences 7,10, leading sometimes to a fast ineluctable arrhythmic  death  in otherwise healthy
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young people despite all usual antiarrhythmic interventions8. Heart transplantation has even been
once performed for such an intractable electrical storm5. That’s why some particular crucial and
efficient therapeutic considerations should be known and urgently applied  in order to avoid a 
fatal outcome.
Figure 1: Repeated onset of polymorphic arrhythmias on ECG monitoring, as could
be observed during electrical storm occurring in patients with Brugada syndrome
Pharmacological Management 
Causal factors should be searched and immediately corrected, such as fever8,15,16, increased vagal
tone during gastro-enteritis6, low potassium blood levels17, non febrile  bronchitis6 or  infusion of
class 1 drugs for diagnostic purposes14,18,19. 
Apart from class 1A agents (see further) no antiarrhythmic drug has been shown to be effective
in preventing recurrence of arrhythmia in Brugada syndrome20,21, then antiarrhythmic drugs
should be better avoided in case of electrical storm. Beta-blocker, bretylate, lidocaine, mexiletine
or magnesium has been tried without any success7,8,11,16 or can even worsen the situation22. In the
DEBUT study, there was an 18 % death rate in Thai patients survivors of Sudden Unexpected
Death Syndrome which were treated with beta-blocker23. If amiodarone infusion has been once
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apparently successful (but concommitantly with a beta-adrenergic agonist, see further)7 , it did
not seem to be beneficial in other cases8,12,16. Sotalol, a drug devoid of class 1 effect, seems to
have been successful in one case7, however, one should remind that class 3 drugs also can
increase ST elevation18,24 that may be deleterious.  
Isoproterenol infusion at a sufficiant dosing, ranging usually from 0.1 to 1-3  µg/mn6,10,18,19,
should be immediately started. Although isoproterenol is generally proarrhythmic in most other
conditions, it is an effective drug in electrical storms related to Brugada syndrome and prevents
recurrences of ventricular fibrillation (VF)6,7, 9-12,21. 
Both Brugada electrocardiographic pattern and ventricular excitability or vulnerability are
believed to be dependent on the sympathetic imbalance and on cardiac rate. Worsening of the
electrophysiological conditions have been described when vagal tonus increases and/or heart rate
decreases22,25. Major arrhythmic events and sudden death are known to frequently occur at night,
when the vagal tone is predominant21. In patients with Brugada syndrome, isoproterenol infusion
normalizes the electrocardiographic pattern and avoids ventricular fibrillation induction during
electrophysiological study 9,11,21.
Beta-adrenergic stimulation with isoproterenol increases ICaL and restores the dome of epicardial
action potentials, reducing the degree of local and transmural heterogeneicity21,26. This can be
sufficient to decrease the degree of ST elevation22 and to avoid the genesis of premature beats.
Beta-adrenergic stimulation should be optimally performed using isoproterenol, since failure of
dobutamine infusion had been reported8, although cilostazol - e.g. an oral phosphodiesterase
inhibitor - has also been shown to be efficient in preventing recurrent VF in Brugada syndrome27.
Accelerating the heart rate (decreasing Ito)28,29 or decreasing the vagal tonus  (decreasing IKAch
and increasing ICaL)26,29  for example by atropine infusion28, can also act, particularly when
associated to beta agonist10. However atropine infusion alone has been sometimes tried without
any beneficial result6, while success30 or failure8,9 of fast pacing have been reported. 
In some cases, VF is incessant despite major adrenergic stimulation due to the physical and
emotional stress caused by the repeated shocks. The associated alpha-adrenergic stimulation,
which is leading to ST elevation in Brugada syndrome21,29, is suspected to overwhelm the
beneficial effects of beta-adrenergic stimulation in those cases6.
Class 1A drugs like quinidine are another means to escape from such a critical situation and
should be tested in patients with electrical storm not immediately responding to isoproterenol.
Oral quinidine has been successfully used in electrical storms in Brugada syndrome10,12,20. 
Quinidine is a class 1 agent and should theoritically worsen the situation because of its sodium
channel blocking properties. However quinidine is also a blocker of the transient outward current
Ito
17, 28,31. Blocking Ito counteracts the marked abbreviation of action potentials in epicardial cells
and so normalizes ECG pattern and ventricular vulnerability. Experimentally, class 1A drugs
restore the action potential dome, normalize ST segment elevation and prevent arrhythmogenesis
by blocking Ito
28. Anticholinergic properties of class 1A agents would also contribute to this
beneficial effect20,28.
In 1987, Belhassen and coll. first document the ability of class 1A agents for prevention of
inducibility in patients with idiopathic VF20, which is believed to be caused in a large part by
Brugada syndrome18,21. Long term beneficial action of quinidine has then been described in a
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population of idiopathic VF and Brugada syndrome32. In this study, lack of inducible arrhythmia
under class 1A drugs (mainly quinidine) was possible in 80 % of patients with the Brugada
syndrome and in all patients with idiopathic VF, and displayed good prognostic value since no
recurrent arrhythmia could be documented after a mean follow-up of 9 years when patients were
treated with class 1A agents (quinidine 1 to 2 g daily)32. In a recent publication of the same
group, quinidine bisulfate at a mean dose of 1.5 g daily prevented inducibility in 88 % of patients
with Brugada syndrome, without any recurrence of arrhythmia with a mean follow-up of  56
months31. Normalization of the ECG pattern and suppression of the ventricular premature beats
as well as the induction of VF by quinidine (1 to 1.5 g daily) has also been described by other
groups in isolated cases12,17,33.
Hydroquinidine chlorydrate (600 to 900 mg daily) has also been recently shown to to normalize
the ECG pattern in 34 % of patients with Brugada syndrome, to prevent arrhythmia inducibility
in 76 % of asymptomatic patients, to prevent the occurrence of arrhythmic events in 90 % of
those patients in which arrhythmia was rendered non inducible, and to avoid any recurrence of
arrhythmia in implanted patients presenting with repeated shocks34.
The effect of others class 1 A drugs is more controversial. Disopyramide, another blocker of Ito,
is believed to be potent but in a lesser extent20,28 : disopyramide can sometimes increase ST
elevation29 and may be proarrhythmic or antiarrhythmic according to the associated conditions20;
in fact it has been shown to prevent inducibility while exagerating the ECG pattern in one case35
and was inefficient in another case11. Procainamide increases ST elevation29 and is proposed for
the drug challenge for diagnosis of Brugada syndrome21 ; it failed to prevent VF induction and to
normalize the ECG pattern in one case of idiopathic VF with right bundle branch, considered as a
variant form of Brugada syndrome33. Other agents which block Ito without significant block of
INa, such as tedisamil, a drug currently in clinical trials for atrial fibrillation, could also be useful
in this situation20.
The only side effect would be an excessive QT prolongation. Because of the blocking action of
class1A drugs on repolarizing K currents, these agents could unmask an associated LQT
syndrome, since some congenital LQT syndrome and Brugada syndrome are both linked to
mutations of the sodium channel and can coexist in the same patients36. Indeed, excessive QT
prolongation in this context has been reported12, although not observed by others17.
            Finally, in case of incessant VF recurring despite all these therapeutic options, general
anesthesia has been sometimes performed with good results5, although failure has  been
reported7,8.
Non Pharmacological Management 
Interventional therapy has been recently developed for treating electrical storm37,38, and appears
promising in such critical situations. Even if ventricular premature beats are rather infrequent in
patients with Brugada syndrome39, ICD-stored electrograms and ECG monitoring have shown
that ventricular premature beats (VPB’s) precede spontaneous VF in the majority of cases and
that they are identical to the one initiating the arrhythmias, which are always induced by the same
premature beat in a given patient40. 
Whether they induced VF or not, VPB’s in Brugada syndrome usually originate from the right
ventricular outflow tract (RVOT)12,19,37 (Figure 2), although right ventricular ectopics with left
axis have been described17,19,37,41. Isolated cases of monomorphic ventricular tachycardia have
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been also reported, with left bundle block morphology with inferior42,43 or superior axis41,44,45 or
even with right bundle block morphology8,14,16, whose relationship with Brugada syndrome could
be incidental or not, but which could also be incessant14  and lead to fatal electrical storm8.
Arrhythmogenic preponderance of the right ventricular outflow tract is not surprising due to the
local higher electrical gradient, as otherwise ilustrated by the ST elevation which is usually
exclusively present in right precordial leads.
Figure 2: 12 lead-ECG with typical ST elevation in right precordial leads and
monomorphic ventricular bigeminy during drug challenge (Ajmaline infusion).
These characteristic ventricular ectopies can be usually documented in Brugada
syndrome, with left bundle block morphology and inferior axis, arising in the right
ventricular outflow tract. These ectopies can trigger multi-recurrent arrhythmias
and have to be targeted by radiofrequency ablation when interventional procedure
is needed.
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Current observations suggest an important role for VPB’s of right ventricular origin in the
Brugada syndrome. Chinushi et al.46  described recurrent episodes of VF in a patient with
Brugada syndrome initiated by monomorphic VPB’s with left bundle block morphology. This
was corroborated by Morita et al.47 who observed VPB’s in 9 out of 45 patients studied. Eleven
VPB morphologies were observed in these 9 patients, of which 10 were of right ventricular
origin (7 lateral RVOT, 2 septal RVOT and 1 from the apex).
While the cornerstone of the management of these conditions has been the implantation of a
defibrillator, these reports and our recent success with the ablation of idiopathic VF48,49 has led
us to evaluate the role of trigger elimination in patients with Brugada syndrome37,50. We have
studied four patients with Brugada syndrome (3 males, age 36 ± 8 years). These patients
presented with documented episodes of polymorphic ventricular tachycardia or VF (1 to 21
episodes), 3 with a family history of sudden death. They had 12 ± 9 episodes of VF or syncope
prior to mapping. No drug therapy had been attempted in 3 patients with Brugada syndrome
while quinidine failed in 1 patient. The Brugada syndrome was diagnosed by abnormal QRST
complexes in leads V1 and V2 with a coved ST segment elevation in 4 patients, one who had a
familial SCN5A channelopathy.  No patient had evidence of structural heart disease based on
physical examination, echocardiography and right/left ventricular ejection fraction. Exercise
testing and coronary angiography excluded myocardial ischemia. Brugada syndrome had been
diagnosed 9 months and 3 years prior to the clinical episodes of VF in 2 patients.
All patients were studied within 2 weeks of their arrhythmic storm and had been documented to
have frequent VPB’s. The triggering role of VPB’s in the initiation of VF was observed by
ambulatory monitoring or stored electrograms of the defibrillator. Premature beats in the Brugada
syndrome were monomorphic in all, coming from the RVOT in three patients (left bundle
branch-inferior axis morphology, coupling interval of 343 ± 59 ms) and with left bundle branch
block-superior axis morphology in one (coupling interval 278 ± 29 ms). The monomorphic
VPB’s were first observed at the time of VF in 2 patients, whereas in 2 patients they had been
documented together with a normal ECG 14 and 11 years before they triggered VF, preceding the
apparition of ECG abnormalities. Exercise testing and isoproterenol infusion eliminated all
premature beats, excluding catecholaminergic polymorphic ventricular tachycardia.
Mapping and ablation was performed as previously described in patients with idiopathic VF49. In
the three patients with RVOT origin, VPB’s were eliminated by 7-10 minutes of radiofrequency
energy applications at the earliest site of activity. In the fourth patient, the VPB’s were found to
originate from the anterior right ventricular Purkinje network. Ten minutes of radiofrequency
energy application eliminated all VPB’s in this patient. Noteworthy is that the inducibility of VF
was modified after ablation. During a mean follow-up period of  9 ± 8 months there has been no
recurrence of VF, syncope or sudden cardiac death in any patient. 
            While catheter ablation techniques are emerging, the initial experiences with idiopathic
VF,  and latterly with VF related to repolarization disorders have provided important insights
into the role of focal triggers from RVOT and the Purkinje system in the initiation of VF
associated with a number of clinical substrates in humans. Reducing the incidence of VF with
localized ablation may reduce defibrillation requirement and replacement and improve the
patients’ quality of life. The excellent long-term results after successful ablation of these triggers
has been confirmed utilizing the data-logging capabilities of defibrillators in many of these
patients and is being achieved in several centers.
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